Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

PURPOSE: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety outcomes. PATIENTS AND METHODS: Patients with previously untreated unresectable stage...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolchok, Jedd D., Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean-Jacques, Rutkowski, Piotr, Lao, Christopher D., Cowey, C. Lance, Schadendorf, Dirk, Wagstaff, John, Dummer, Reinhard, Ferrucci, Pier Francesco, Smylie, Michael, Butler, Marcus O., Hill, Andrew, Márquez-Rodas, Ivan, Haanen, John B. A. G., Guidoboni, Massimo, Maio, Michele, Schöffski, Patrick, Carlino, Matteo S., Lebbé, Céleste, McArthur, Grant, Ascierto, Paolo A., Daniels, Gregory A., Long, Georgina V., Bas, Tuba, Ritchings, Corey, Larkin, James, Hodi, F. Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718224/
https://www.ncbi.nlm.nih.gov/pubmed/34818112
http://dx.doi.org/10.1200/JCO.21.02229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718224/
https://www.ncbi.nlm.nih.gov/pubmed/34818112
http://dx.doi.org/10.1200/JCO.21.02229

Ejemplares similares